Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL.
作者信息
Picardi Marco, Della Pepa Roberta, Giordano Claudia, Zacheo Irene, Pugliese Novella, Mortaruolo Chiara, Trastulli Fabio, Giordano Antonio, Lucignano Mariano, Di Perna Maria, Raimondo Marta, Salvatore Claudia, Pane Fabrizio
机构信息
Department of Advanced Biomedical Sciences and.
Department of Clinical Medicine and Surgery, Federico II University Medical, School, Naples, Italy; and.
出版信息
Blood. 2019 Jan 31;133(5):498-501. doi: 10.1182/blood-2018-10-878892. Epub 2018 Dec 7.
Abstract
摘要
相似文献
1
Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL.替诺福韦与拉米夫定预防晚期弥漫大B细胞淋巴瘤患者乙肝病毒再激活的疗效比较
Blood. 2019 Jan 31;133(5):498-501. doi: 10.1182/blood-2018-10-878892. Epub 2018 Dec 7.
2
Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy.核苷（酸）类似物在接受细胞毒性化疗的慢性乙型肝炎患者中的比较疗效。
Asia Pac J Clin Oncol. 2016 Dec;12(4):421-429. doi: 10.1111/ajco.12520. Epub 2016 Jul 20.
3
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.用于预防血液系统恶性肿瘤免疫抑制患者乙肝病毒再激活的核苷（酸）类似物：一项网状Meta分析
Expert Rev Anti Infect Ther. 2017 May;15(5):503-513. doi: 10.1080/14787210.2017.1309291. Epub 2017 Mar 29.
4
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.恩替卡韦与拉米夫定预防未治疗弥漫性大 B 细胞淋巴瘤接受 R-CHOP 化疗患者乙型肝炎病毒再激活：一项随机临床试验。
JAMA. 2014 Dec 17;312(23):2521-30. doi: 10.1001/jama.2014.15704.
5
Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.抢先使用阿德福韦与拉米夫定预防接受化疗的慢性乙型肝炎患者乙肝再激活的比较
Hepatol Int. 2015 Apr;9(2):224-30. doi: 10.1007/s12072-015-9612-6. Epub 2015 Mar 12.
6
Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma.拉米夫定预防非霍奇金淋巴瘤患者接受治疗时乙肝病毒再激活的疗效。
Blood. 2002 Jan 15;99(2):724-5. doi: 10.1182/blood.v99.2.724.
7
Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.十八个月拉米夫定预防在接受免疫抑制治疗的血液系统恶性肿瘤患者中预防隐匿性乙型肝炎病毒感染再激活的作用
J Viral Hepat. 2018 Feb;25(2):198-204. doi: 10.1111/jvh.12802. Epub 2017 Nov 29.
8
Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients.预防性使用拉米夫定可预防化疗患者的乙型肝炎再激活。
Aliment Pharmacol Ther. 2002 Nov;16(11):1939-44. doi: 10.1046/j.1365-2036.2002.01364.x.
9
Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation.坚持进行乙肝筛查并使用预防性拉米夫定以预防利妥昔单抗相关的乙肝再激活。
J Oncol Pharm Pract. 2013 Mar;19(1):18-23. doi: 10.1177/1078155212447975. Epub 2012 May 25.
10
Antiviral prophylaxis for hepatitis B carriers affected by diffuse large B cell lymphoma: a matter of survival.
Br J Haematol. 2021 Jan;192(1):11-12. doi: 10.1111/bjh.17143. Epub 2020 Oct 31.
引用本文的文献
1
Risk of Non-Hodgkin Lymphoma among Patients with Hepatitis B Virus and Hepatitis C Virus in Taiwan: A Nationwide Cohort Study.台湾地区乙肝病毒和丙肝病毒感染者中非霍奇金淋巴瘤的风险：一项全国性队列研究
Cancers (Basel). 2022 Jan 24;14(3):583. doi: 10.3390/cancers14030583.
2
Liver failure from delayed hepatitis B reactivation in anti-HBc-positive patient following rituximab for B-cell lymphoma.利妥昔单抗治疗 B 细胞淋巴瘤后乙型肝炎核心抗体阳性患者发生乙型肝炎再激活致肝衰竭
BMJ Case Rep. 2021 Jul 9;14(7):e243526. doi: 10.1136/bcr-2021-243526.
3
Regarding "Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era".关于“在利妥昔单抗时代，乙型肝炎表面抗原阳性是弥漫性大 B 细胞淋巴瘤的一个独立的不良预后因素”。
Oncologist. 2021 Jun;26(6):e1083-e1084. doi: 10.1002/onco.13710. Epub 2021 Feb 24.
4
Correspondence in reference to the previously published Epub manuscript: "Murt Ahmet et al. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country. Annals of Hematology 2020; 99: 2671-2677".关于之前发表的在线优先出版手稿的通信：“穆尔特·艾哈迈德等人。造血干细胞移植患者中的乙型肝炎再激活：一个中等流行国家单一中心的20年经验。《血液学杂志》2020年；99：2671 - 2677”
Ann Hematol. 2021 Jun;100(6):1631-1633. doi: 10.1007/s00277-021-04436-9. Epub 2021 Feb 1.
5
Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation.富马酸替诺福韦二吡呋酯与恩替卡韦预防 HBV 再激活的比较。
Dig Dis Sci. 2021 Jul;66(7):2417-2426. doi: 10.1007/s10620-020-06506-w. Epub 2020 Jul 29.
6
Reactivation of Hepatitis B Virus: A Review of Clinical Guidelines.乙型肝炎病毒再激活：临床指南综述
Clin Liver Dis (Hoboken). 2020 May 7;15(4):162-167. doi: 10.1002/cld.883. eCollection 2020 Apr.
7
Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators.将与生物制剂和靶向免疫调节剂相关的感染风险降至最低的预防策略。
Infect Drug Resist. 2020 Feb 18;13:513-532. doi: 10.2147/IDR.S233137. eCollection 2020.
8
Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma.多发性骨髓瘤患者中乙型肝炎病毒的再激活
Cancers (Basel). 2019 Nov 19;11(11):1819. doi: 10.3390/cancers11111819.
本文引用的文献
1
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.EASL 2017 临床实践指南：乙型肝炎病毒感染管理。
J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18.
2
Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma.隐匿性乙肝病毒感染或丙肝抗体阳性的淋巴瘤患者的病毒转归情况
Ann Hepatol. 2017 March-April;16(2):198-206. doi: 10.5604/16652681.1231567.
3
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.接受抗癌治疗的血液系统恶性肿瘤患者中乙型肝炎病毒再激活的预防与管理
World J Gastroenterol. 2016 Jul 28;22(28):6484-500. doi: 10.3748/wjg.v22.i28.6484.
4
Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.系统评价与网状Meta分析：口服核苷（酸）类似物预防化疗引起的乙型肝炎病毒再激活的比较疗效
Oncotarget. 2016 May 24;7(21):30642-58. doi: 10.18632/oncotarget.8907.
5
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.《世界卫生组织淋巴组织肿瘤分类（2016年修订版）》
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.
6
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.恩替卡韦与拉米夫定预防未治疗弥漫性大 B 细胞淋巴瘤接受 R-CHOP 化疗患者乙型肝炎病毒再激活：一项随机临床试验。
JAMA. 2014 Dec 17;312(23):2521-30. doi: 10.1001/jama.2014.15704.
7
American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.美国胃肠病学会关于免疫抑制药物治疗期间预防和治疗乙型肝炎病毒再激活的技术审查
Gastroenterology. 2015 Jan;148(1):221-244.e3. doi: 10.1053/j.gastro.2014.10.038. Epub 2014 Oct 31.
8
The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center.替诺福韦在预防和治疗免疫抑制患者乙肝病毒（HBV）再激活中的作用。来自三级中心的真实病例经验。
Eur J Intern Med. 2014 Oct;25(8):768-71. doi: 10.1016/j.ejim.2014.06.028. Epub 2014 Jul 16.
9
Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.利妥昔单抗治疗的 B 细胞淋巴瘤患者乙型肝炎病毒再激活：亚洲淋巴瘤研究组的分析。
Eur J Cancer. 2013 Nov;49(16):3486-96. doi: 10.1016/j.ejca.2013.07.006. Epub 2013 Aug 1.
10
Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.恩替卡韦与拉米夫定用于血液病患者乙型肝炎的预防。
Liver Int. 2013 Sep;33(8):1203-10. doi: 10.1111/liv.12154. Epub 2013 Mar 24.
Zotero 插件